ClinicalTrials.gg
Drug

Ivarmacitinib clinical trials

Also written SHR0302.

studies test it
42
open now
19
in phase 3
8
first study started
2015

How each study uses ivarmacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ivarmacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ivarmacitinib
9
Ivarmacitinib Sulfate Tablets
4
SHR0302 Base Gel
2
SHR0302 Tablets
2

Development codes

SHR0302
18

Studies by the year they started

42 studies that test it; most in 2026 (12)

Studies that test ivarmacitinib, by start year
YearStudies
20151
20162
20171
20193
20206
20213
20223
20232
20243
20256
202612

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
19
Phase 3
8
Phase 4
3
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 19

Jiangsu HengRui Medicine Co., Ltd. (15) · Reistone Biopharma Company Limited (8) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Chinese SLE Treatment And Research Group (2) · Peking University Third Hospital (1) · Huijie Zhang (1) · Peking University People's Hospital (1) · Tongji Hospital (1)

Often tested with

Tested in the same studies.

Camrelizumab (2) · Celecoxib (1) · Immune checkpoint inhibitors (1) · HMPL-013 (1) · Antilymphocyte Serum (1) · Zeprumetostat (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test ivarmacitinib.

Studies

Open first, then newest update. How each study uses ivarmacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 42

See all 42 studies that test ivarmacitinib →

Given beside what is tested · 1 — ivarmacitinib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with ivarmacitinib

Codes

What other systems call ivarmacitinib · ClinicalTrials.gg INT000650

  • MeSH (NLM) C000615713ivarmacitinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) K6K4B9Z5TVIVARMACITINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q123499437ivarmacitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C186403IvarmacitinibOne source FDA

Also registered as ivarmacitinib sulfate (UNII CN7B3Z5G04).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.